Sponsored By:

8 Biotechnology Stocks to Sell Now

MACK, GHDX, ACOR, AMRN, EXEL, TSRX, DSCO, ACHN slump in weekly rankings

   

The ratings of eight Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) ratings are on the decline this week as the company earns an F (“strong sell”). Last week, it received a D (“sell”). Merrimack Pharmaceuticals is a biotechnology company, which is focused on the discovery, development and commercialization of drugs for the treatment of immunological and autoimmune diseases with an initial focus on cancer. In Portfolio Grader’s specific subcategories of Earnings Revisions and Cash Flow, MACK also gets F’s. As of Sept. 25, 2013, 12.4% of outstanding Merrimack Pharmaceuticals, Inc. shares were held short. For a full analysis of MACK stock, visit Portfolio Grader.

Genomic Health, Inc. (NASDAQ:GHDX) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock’s trailing PE Ratio is 854.30. To get an in-depth look at GHDX, get Portfolio Grader’s complete analysis of GHDX stock.

The rating of Acorda Therapeutics, Inc. (NASDAQ:ACOR) declines this week from a C to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

This week, Amarin Corporation Plc Sponsored ADR (NASDAQ:AMRN) drops from a C to a D rating. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. In Earnings Growth, Earnings Revisions, Equity, and Cash Flow the stock gets F’s. As of Sept. 25, 2013, 13.7% of outstanding Amarin Corporation Plc Sponsored ADR shares were held short. For a full analysis of AMRN stock, visit Portfolio Grader.

This is a rough week for Exelixis, Inc. (NASDAQ:EXEL). The company’s rating falls to F from the previous week’s D. Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. As of Sept. 25, 2013, 21.9% of outstanding Exelixis, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of EXEL stock.

This week, Trius Therapeutics, Inc.’s (NASDAQ:TSRX) rating worsens to a D from the company’s C rating a week ago. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

The rating of Discovery Laboratories, Inc. (NASDAQ:DSCO) slips from a C to a D. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. The stock gets F’s in Equity and Cash Flow. For a full analysis of DSCO stock, visit Portfolio Grader.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is having a tough week. The company’s rating falls from a C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. As of Sept. 25, 2013, 15.5% of outstanding Achillion Pharmaceuticals, Inc. shares were held short. To get an in-depth look at ACHN, get Portfolio Grader’s complete analysis of ACHN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/09/8-biotechnology-stocks-to-sell-now-mack-ghdx-acor-3/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.